|
|
D-Murapalmitine |
|
Vaxjo ID |
66 |
|
Vaccine Adjuvant Name |
D-Murapalmitine |
|
Alternative Names |
Nac-Mur-D-Ala-D-isoGln-sn-glycerol dipalmitoyl |
|
Adjuvant VO ID |
VO_0001305
|
|
Description |
D-Murapalmitine will be developed as an adjuvant for vaccines likely to contain autoantigens. Administered in water-in-oil (w/o) emulsion as adjuvant of humoral and cell-mediated immunity (Vogel and Powell, 1995). |
|
Stage of Development |
Research |
|
Components |
Nac-Mur-D-Ala-D-isoGln-sn-glycerol dipalmitoyl (Vogel and Powell, 1995). |
|
Molecular Weight |
1056 |
|
Appearance |
White powder. |
|
Storage |
Stored as a powder at 4° C. Protect from light and humidity (Vogel and Powell, 1995). |
|
Function |
D-Murapalmitine is a strong adjuvant of humoral and cell-mediated immunity when administered in a 50% mineral oil emulsion. However, in contrast with other MDPs, it does not induce experimental allergic encephalomyelitis (EAE) when administered with myelin basic protein. When given with an antigenic preparation containing hetero and autologous epitopes, it favors the response to the heterologous determinants (Vogel and Powell, 1995). |
|
Safety |
This MDP analog is non-pyrogenic in rabbits and displays no acute toxicity when tested in mice, rats, guinea pigs, and rabbits. Further toxicological studies will be performed (Vogel and Powell, 1995). |
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
